Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2013
Source ID
10.1016/j.nicl.2013.07.006

Entities

People

  • Arthur W. Toga
  • Clifford Jack
  • Julio E. Villalon-reina
  • Michael W. Weiner
  • Neda Jahanshad
  • Paul M. Thompson
  • Talia M. Nir

Organizations

  • Abbott Laboratories
  • Alzheimer's Association
  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's Drug Discovery Foundation
  • Amorfix (Canada)
  • AstraZeneca
  • Bayer HealthCare
  • BioClinica
  • Canadian Institutes of Health Research
  • Chiron Corporation
  • Eli Lilly and Company
  • GE HealthCare
  • Hoffmann-La Roche
  • Johnson & Johnson Pharmaceutical Research and Development
  • Laboratoires Servier
  • Medpace
  • Merck & Co.
  • Meso Scale Diagnostics (United States)
  • National Center for Research Resources
  • National Institute of Biomedical Imaging and Bioengineering
  • National Institute on Aging
  • National Institutes of Health
  • Pfizer
  • Roche (United States)
  • Takeda Pharmaceutical Company
  • United States National Library of Medicine